275 related articles for article (PubMed ID: 29317695)
1. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease.
Batta G; Soltész L; Kovács T; Bozó T; Mészár Z; Kellermayer M; Szöllősi J; Nagy P
Sci Rep; 2018 Jan; 8(1):157. PubMed ID: 29317695
[TBL] [Abstract][Full Text] [Related]
2. Selective reduction of bis(monoacylglycero)phosphate ameliorates the storage burden in a THP-1 macrophage model of Gaucher disease.
Hein LK; Duplock S; Fuller M
J Lipid Res; 2013 Jun; 54(6):1691-1697. PubMed ID: 23564732
[TBL] [Abstract][Full Text] [Related]
3. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
[TBL] [Abstract][Full Text] [Related]
4. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.
Karageorgos L; Hein L; Rozaklis T; Adams M; Duplock S; Snel M; Hemsley K; Kuchel T; Smith N; Hopwood JJ
Neurobiol Dis; 2016 Jul; 91():143-54. PubMed ID: 26976737
[TBL] [Abstract][Full Text] [Related]
5. Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
[TBL] [Abstract][Full Text] [Related]
6. Lipid composition of membrane rafts, isolated with and without detergent, from the spleen of a mouse model of Gaucher disease.
Hattersley KJ; Hein LK; Fuller M
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):62-7. PubMed ID: 24220330
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases.
Ferraz MJ; Marques AR; Appelman MD; Verhoek M; Strijland A; Mirzaian M; Scheij S; Ouairy CM; Lahav D; Wisse P; Overkleeft HS; Boot RG; Aerts JM
FEBS Lett; 2016 Mar; 590(6):716-25. PubMed ID: 26898341
[TBL] [Abstract][Full Text] [Related]
8. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts.
Saito M; Rosenberg A
J Biol Chem; 1985 Feb; 260(4):2295-300. PubMed ID: 3919000
[TBL] [Abstract][Full Text] [Related]
9. Lipid composition of microdomains is altered in neuronopathic Gaucher disease sheep brain and spleen.
Hein LK; Rozaklis T; Adams MK; Hopwood JJ; Karageorgos L
Mol Genet Metab; 2017 Jul; 121(3):259-270. PubMed ID: 28532689
[TBL] [Abstract][Full Text] [Related]
10. Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.
Reed MC; Schiffer C; Heales S; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Aug; 124(4):278-286. PubMed ID: 29934064
[TBL] [Abstract][Full Text] [Related]
11. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
Sawkar AR; D'Haeze W; Kelly JW
Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
[TBL] [Abstract][Full Text] [Related]
13. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease.
Aerts JMFG; Kuo CL; Lelieveld LT; Boer DEC; van der Lienden MJC; Overkleeft HS; Artola M
Curr Opin Chem Biol; 2019 Dec; 53():204-215. PubMed ID: 31783225
[TBL] [Abstract][Full Text] [Related]
14. Effect of sterol carrier protein-2 expression on sphingolipid distribution in plasma membrane lipid rafts/caveolae.
Atshaves BP; Jefferson JR; McIntosh AL; Gallegos A; McCann BM; Landrock KK; Kier AB; Schroeder F
Lipids; 2007 Oct; 42(10):871-84. PubMed ID: 17680294
[TBL] [Abstract][Full Text] [Related]
15. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration.
Lunghi G; Carsana EV; Loberto N; Cioccarelli L; Prioni S; Mauri L; Bassi R; Duga S; Straniero L; Asselta R; Soldà G; Di Fonzo A; Frattini E; Magni M; Liessi N; Armirotti A; Ferrari E; Samarani M; Aureli M
Cells; 2022 Jul; 11(15):. PubMed ID: 35954187
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipid symmetry governs membrane lipid raft structure.
Quinn PJ
Biochim Biophys Acta; 2014 Jul; 1838(7):1922-30. PubMed ID: 24613791
[TBL] [Abstract][Full Text] [Related]
17. Sphingolipid microdomains mediate CD38 internalization: topography of the endocytosis.
Trubiani O; Guarnieri S; Orciani M; Salvolini E; Di Primio R
Int J Immunopathol Pharmacol; 2004; 17(3):293-300. PubMed ID: 15461863
[TBL] [Abstract][Full Text] [Related]
18. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.
Langeveld M; Ghauharali KJ; Sauerwein HP; Ackermans MT; Groener JE; Hollak CE; Aerts JM; Serlie MJ
J Clin Endocrinol Metab; 2008 Mar; 93(3):845-51. PubMed ID: 18089699
[TBL] [Abstract][Full Text] [Related]
19. Induction of the type I interferon response in neurological forms of Gaucher disease.
Vitner EB; Farfel-Becker T; Ferreira NS; Leshkowitz D; Sharma P; Lang KS; Futerman AH
J Neuroinflammation; 2016 May; 13(1):104. PubMed ID: 27175482
[TBL] [Abstract][Full Text] [Related]
20. New insights into glycosphingolipid functions--storage, lipid rafts, and translocators.
Sillence DJ
Int Rev Cytol; 2007; 262():151-89. PubMed ID: 17631188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
